Editor's note: The story was updated with analyst comments. With billions in sales under biosimilar threat and facing investor pressure to make M&A moves, Amgen on Wednesday posted revenue and earnings beats for the second quarter. The results, boosted by pharma's much-maligned price increases, were enough for the California biotech to raise its guidance following a solid first half. Amgen ($AMGN) reported Enbrel sales growth of 10% to $1.48 billion in the second quarter, a rise driven by price increases that were offset somewhat by competition, executives explained on a conference call.